SCHEMBL614481

SCHEMBL614481

CNCC1Cc2cc(F)c(OC(C)NS(=O)(=O)CC3CC3)cc2C1Cc1cccc(C(F)(F)F)c1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A9 P48067 2/20 0.34
GALR3 O60755 1/20 0.33
TACR1 P25103 1/20 0.32
SLC6A4 P31645 2/20 0.32
SLC6A2 P23975 1/20 0.32
LMNA P02545 2/20 0.31
CARM1 Q86X55 2/20 0.31
PRMT6 Q96LA8 2/20 0.31
GAA P10253 1/20 0.31
KMT2A Q03164 2/20 0.30
HTT P42858 1/20 0.30
RAB9A P51151 1/20 0.30
IDE P14735 1/20 0.30
PAX8 Q06710 1/20 0.30
SIGMAR1 Q99720 1/20 0.30
MAPT P10636 1/20 0.30
ADRA2C P18825 1/20 0.30
HTR2A P28223 1/20 0.30
ADRA1A P35348 1/20 0.30
DRD3 P35462 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL614482 0.85 SLC6A9 (0.46) SLC6A9GALR3TACR1SLC6A4SLC6A2
SCHEMBL615175 0.82 GALR3 (0.40) SLC6A9GALR3TACR1SLC6A4SLC6A2
SCHEMBL615031 0.81 SLC6A9 (0.40) SLC6A9GALR3TACR1SLC6A4SLC6A2
SCHEMBL615918 0.79 GALR3 (0.44) SLC6A9GALR3TACR1SLC6A4SLC6A2
SCHEMBL614428 0.77 SLC6A9 (0.43) SLC6A9GALR3SLC6A4SLC6A2CARM1
SCHEMBL615678 0.77 SLC6A9 (0.42) SLC6A9GALR3TACR1SLC6A4SLC6A2
SCHEMBL605995 0.76 SLC6A9 (0.53) SLC6A9GALR3CARM1PRMT6
SCHEMBL614722 0.76 SLC6A9 (0.59) SLC6A9GALR3SLC6A4SLC6A2
SCHEMBL617083 0.75 SLC6A9 (0.49) SLC6A9
SCHEMBL615463 0.74 GALR3 (0.35) SLC6A9GALR3TACR1SLC6A4SLC6A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8883839-B2 Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy ABBOTT LABORATORIES (US) 2014-11-11 US claimed
US-20120040947-A1 TETRALINE AND INDANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY ABBOTT LABORATORIES (US) 2012-02-16 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120040947-A1 TETRALINE AND INDANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY SLC10A1, SUGT1, SLC10A2 SLC6A9 42/4885GALR3 462/4885TACR1 1057/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.